Current SCD Studies (2):
• GBT 133- Open-label Extension Study to Evaluate the Long-term Safety of Inclacumab IV Administered to Participants ≥ 12years with Sickle Cell Disease Who Have Participated in a Inclacumab Clinical Trial. • HIBISCUS -This study is enrolling subjects between 12 and 65 years old who have been diagnosed with SCD. The purpose of this study is to evaluate the safety and effectiveness of an oral investigational medication for sickle cell disease. • Fulcrum - Phase 1, Open-Label, study evaluating the safety and Tolerability, Pharmacokinetics and Pharmacodynamics of an oral drug in Subjects 18-65 years with Sickle Cell Disease (SCD).
Made with FlippingBook Digital Proposal Creator